Recursion Pharmaceuticals, Inc. (RXRX) Debt by Year
Recursion Pharmaceuticals, Inc. carried $9.6M in long-term debt against $743.3M in cash and equivalents at the end of fiscal year 2025. This represents a decrease of 49.7% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Recursion Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
RXRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
RXRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $4.8M-66.5% | $7.2M-56.3% | $9.6M-49.7% | $11.9M-42.0% | $14.2M-38.1% | $16.4M | $19.0M+1627.7% | $20.5M | $22.9M | N/A | $1.1M | N/A |
| Cash & Equivalents | $545.7M+3.9% | $654.5M+30.8% | $743.3M+25.1% | $659.8M+54.3% | $525.1M+10.7% | $500.5M+68.9% | $594.4M+51.8% | $427.6M+10.4% | $474.3M+16.9% | $296.3M-37.4% | $391.6M-28.8% | $387.3M-14.8% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Recursion Pharmaceuticals, Inc. financials
Frequently Asked Questions
What was Recursion Pharmaceuticals, Inc.'s long-term debt in fiscal year 2025?
Recursion Pharmaceuticals, Inc. carried $9.6M in long-term debt against $743.3M in cash and equivalents at the end of fiscal year 2025.
How fast is Recursion Pharmaceuticals, Inc.'s long-term debt growing?
Recursion Pharmaceuticals, Inc. (RXRX) long-term debt fell by 49.7% year over year, from $19.0M to $9.6M in fiscal year 2025.
What was Recursion Pharmaceuticals, Inc.'s long-term debt in the most recent quarter?
Recursion Pharmaceuticals, Inc. (RXRX) reported $4.8M in long-term debt in Q2 2026. This represents a decrease of 66.5% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Recursion Pharmaceuticals, Inc. (RXRX) reported on that line in every period on record.